43 results about "Dosing schedules" patented technology

An automated adaptive radiotherapy system based on machine learning for designing and adapting personalized dosing plans and a corresponding system, the system comprising: • a data acquisition module to collect multimodal patient data such as anatomical images, genomics, physiological signals and electronic health records; • a preprocessing department that performs the normalization, alignment, segmentation and transformation of the acquired data into data structures suitable for predictive modeling; • a dose prediction engine containing at least one machine learning model trained to predict personalized three-dimensional radiotherapy dose distributions and dose-volume histograms from the preprocessed data; • an adaptation module to receive updated clinical data and automatically adapt the dosing schedule to intra-fraction and inter-fraction changes in patient anatomy and response to treatment; • a clinician dashboard that displays predicted dosing schedules, allows clinician interaction, and can make the model interpretable through explainable AI; • a data security and compliance layer that protects data through encryption, access control, and regulatory compliance.

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.

The present disclosure provides a caregiver system and method for interfacing with and controlling an oral medication dispensing device. The system registers the caregiver and provides the caregiver a list of patients under the caregiver's care, as well as associated medication dose schedules for each of the one or more patients. The caregiver is provided reminders regarding doses and allowed to modify the dose schedule to generate a modified dose schedule. The modified does schedule is pushed to a patient system associated with a medication dispensing device.

The present disclosure provides a caregiver system and method for interfacing with and controlling an oral medication dispensing device. The system registers the caregiver and provides the caregiver a list of patients under the caregiver's care, as well as associated medication dose schedules for each of the one or more patients. The caregiver is provided reminders regarding doses and allowed to modify the dose schedule to generate a modified dose schedule. The modified does schedule is pushed to a patient system associated with a medication dispensing device.

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.

The disclosure provides compositions and improved methods for the treatment of cancer comprising administering to a patient the fusion protein of SEQ ID NO: 1 at a less frequent dosing schedule (i.e., a single administration every three weeks or multiple administrations on non-consecutive days).

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.

Provided herein are pharmaceutical formulations of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form. Also provided herein are methods of treating cancer comprising a pharmaceutical formulation of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form.

A non-transitory computer readable storage medium comprising instructions that, when executed by a computer, cause the computer to execute a program for managing a user's medical condition or treatment; monitor a current dosing schedule set within the program; determine whether a scheduled dose is due; determine an experience level of a user; in response to determining that the scheduled dose is due, generate a first notification alerting the user to the scheduled dose; and in response to detecting user interaction with the first notification, provide a user interface displaying content relating to the scheduled dose. At least part of the content displayed is based on the experience level of the user.

A non-transitory computer readable storage medium, user device and method configured to execute a program for managing a user's medical condition or treatment. When the program determines that a time period for taking a scheduled dose has been exceeded by more than a lower threshold time, it causes a late dose notification to be displayed. When a user interacts with the late dose notification, the program provides options for the user to (i) indicate that they have taken the scheduled dose or (ii) indicate that they have not taken the scheduled dose. When the user indicates that they have taken the scheduled dose after the lower threshold time, the program provides options for the user to (i) reset the current medicament dosing schedule or (ii) maintain the current medicament dosing schedule.

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Such devices may measure the level of an analyte and deliver medicament with the intent of maintaining the analyte at a target level or in a target range. The described methods and apparatuses apply a model to evaluate an effect of proposed future medicament doses on predicted analyte levels. The proposed future medicament doses and predicted analyte levels may be supplied to a cost function to select which of the proposed future medicament dose schedules results in optimal control of the predicted analyte levels. The cost function may apply a weighting scheme that weighs predictions in the near- and / or medium-term future more than longer-term predictions.

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in the claims for use in the treatment of a neoplastic disease in a subject, wherein said treatment comprises administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the subject according to an intermittent dosing schedule.

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a GPRC5DxCD3 bispecific antibody according to a monthly administration schedule.

A method of treating cancer in a subject in need thereof, wherein the method comprises administration of therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, or administration of therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to the dosing schedules described herein.

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a novel dosing schedule.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.

A non-transitory computer-readable storage medium, a user device, and a method configured to execute a program for managing a medical condition or treatment of a user are provided. When the procedure determines that the period of time for taking the predetermined dose has been exceeded by more than a lower threshold time, the procedure causes a late dose notification to be displayed. When a user interacts with the late dose notification, the program provides the user with an option to (i) indicate that they have taken the predetermined dose or (ii) indicate that they have not taken the predetermined dose. When the user indicates that they have taken the predetermined dose after the lower threshold time, the procedure provides the user with an option to (i) reset the current medicament administration schedule or (ii) maintain the current medicament administration schedule.

The invention relates to the cross field of toxicology and immunology, in particular to an intervention method for relieving T-2 toxin induced cellular immune aging based on PER2 protein inhibition and application of the intervention method. The method comprises the following steps: S1, providing an exposed object containing immune cells in an in-vitro culture system; s2, firstly applying a PER2 inhibitor; s3, sequentially finishing S2 and T-2 treatment according to a preset initial administration time interval; and S4, characterizing the Hippo pathway MST1 / YAP / p-YAP in 4 hours and / or 12 hours after T-2 treatment, and obtaining p-YAP subcellular localization, thereby determining or adjusting the administration time course. According to the scheme, closed-loop standard operation and parameter setting are carried out according to'administration-detection-time history determination '.

A pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide is provided herein. A method for treating cancer is also provided herein, comprising a pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide.

The present disclosure provides a physician system and method for interfacing with and controlling an oral medication dispensing device. The system registers a patient under the care of a doctor and records a dose schedule for the patient. The dose schedule specifies a particular medication and associated volume and timing interval for administration to the patient via a medication dispensing device. A medication cartridge is with the dose schedule. An invitation link is sent to the patient for the patient to link the physician system with their patient system and the medication dispensing device. The dose schedule can be pushed to the patient system to populate the patient system with the specifics of the dose schedule.

The present invention relates to dosing schedules for HER2 inhibitors useful in the prevention and / or treatment of cancer, in particular to doses thereof and / or the administration of a second or additional line.

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.

The present invention relates to a drug administration schedule for HER2 inhibitors useful in the prevention and / or treatment of cancer, particularly to their dosage and administration in second-line or subsequent lines.